Investors are keeping a close eye on Vertex as the PDUFA date approaches, with the potential approval of suzetrigine marking ...
Cantor Fitzgerald reaffirmed its Overweight rating on ALX Oncology (NASDAQ:ALXO), following the presentation of positive Phase 2 ASPEN-6 study results. According to InvestingPro data, the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback